カテゴリー： 世界, 医療/バイオ, LP Information

世界の多価肺炎球菌複合体ワクチン市場予測 2023年-2029年

【英語タイトル】Global Multivalent Pneumococcal Conjugate Vaccine Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC05671）・商品コード：LP23DC05671
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：97
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の多価肺炎球菌複合体ワクチン市場」は、過去の販売実績から2022年の世界の多価肺炎球菌複合体ワクチンの総販売量を検討し、2023年から2029年の予測される多価肺炎球菌複合体ワクチンの販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の多価肺炎球菌複合体ワクチンの市場規模を掲載し、XXX百万米ドル規模の世界の多価肺炎球菌複合体ワクチン市場の詳細な分析を提供します。本インサイトレポートは、世界の多価肺炎球菌複合体ワクチン業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の多価肺炎球菌複合体ワクチン市場における各社の独自のポジションをより深く理解するために、多価肺炎球菌複合体ワクチン製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の多価肺炎球菌複合体ワクチン市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。多価肺炎球菌複合体ワクチンの米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。多価肺炎球菌複合体ワクチンの中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。多価肺炎球菌複合体ワクチンのヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

多価肺炎球菌複合体ワクチンの世界主要メーカーとしては、Merck Sharp & Dohme Corp、 Pfizer、 CanSino Bio、 Serum Institute of India Pvt. Ltd.、 Shanghai Weizhou Biotechnology Co., Ltd.などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の多価肺炎球菌複合体ワクチン市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では多価肺炎球菌複合体ワクチン市場をセグメンテーションし、種類別 (13価格、20価格、23価格、24価格)、用途別 (病院、外来センター、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：13価格、20価格、23価格、24価格

・用途別区分：病院、外来センター、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の多価肺炎球菌複合体ワクチン市場の10年間の市場状況・展望は？
・世界および地域別に見た多価肺炎球菌複合体ワクチン市場成長の要因は何か？
・多価肺炎球菌複合体ワクチンの市場機会はエンドマーケットの規模によってどのように変化するのか？
・多価肺炎球菌複合体ワクチンのタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：多価肺炎球菌複合体ワクチンの年間販売量2018-2029、地域別現状・将来分析
・多価肺炎球菌複合体ワクチンの種類別セグメント：13価格、20価格、23価格、24価格
・多価肺炎球菌複合体ワクチンの種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・多価肺炎球菌複合体ワクチンの用途別セグメント：病院、外来センター、その他
・多価肺炎球菌複合体ワクチンの用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の多価肺炎球菌複合体ワクチン市場
・企業別のグローバル多価肺炎球菌複合体ワクチン市場データ：2018-2023年の年間販売量、市場シェア
・企業別の多価肺炎球菌複合体ワクチンの年間売上：2018-2023年の売上、市場シェア
・企業別の多価肺炎球菌複合体ワクチン販売価格
・主要企業の多価肺炎球菌複合体ワクチン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

多価肺炎球菌複合体ワクチンの地域別レビュー
・地域別の多価肺炎球菌複合体ワクチン市場規模2018-2023：年間販売量、売上
・主要国別の多価肺炎球菌複合体ワクチン市場規模2018-2023：年間販売量、売上
・南北アメリカの多価肺炎球菌複合体ワクチン販売の成長
・アジア太平洋の多価肺炎球菌複合体ワクチン販売の成長
・ヨーロッパの多価肺炎球菌複合体ワクチン販売の成長
・中東・アフリカの多価肺炎球菌複合体ワクチン販売の成長

南北アメリカ市場
・南北アメリカの国別の多価肺炎球菌複合体ワクチン販売量、売上（2018-2023）
・南北アメリカの多価肺炎球菌複合体ワクチンの種類別販売量
・南北アメリカの多価肺炎球菌複合体ワクチンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の多価肺炎球菌複合体ワクチン販売量、売上（2018-2023）
・アジア太平洋の多価肺炎球菌複合体ワクチンの種類別販売量
・アジア太平洋の多価肺炎球菌複合体ワクチンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の多価肺炎球菌複合体ワクチン販売量、売上（2018-2023）
・ヨーロッパの多価肺炎球菌複合体ワクチンの種類別販売量
・ヨーロッパの多価肺炎球菌複合体ワクチンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の多価肺炎球菌複合体ワクチン販売量、売上（2018-2023）
・中東・アフリカの多価肺炎球菌複合体ワクチンの種類別販売量
・中東・アフリカの多価肺炎球菌複合体ワクチンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・多価肺炎球菌複合体ワクチンの製造コスト構造分析
・多価肺炎球菌複合体ワクチンの製造プロセス分析
・多価肺炎球菌複合体ワクチンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・多価肺炎球菌複合体ワクチンの主要なグローバル販売業者
・多価肺炎球菌複合体ワクチンの主要なグローバル顧客

地域別の多価肺炎球菌複合体ワクチン市場予測レビュー
・地域別の多価肺炎球菌複合体ワクチン市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・多価肺炎球菌複合体ワクチンの種類別市場規模予測
・多価肺炎球菌複合体ワクチンの用途別市場規模予測

主要企業分析
Merck Sharp & Dohme Corp、 Pfizer、 CanSino Bio、 Serum Institute of India Pvt. Ltd.、 Shanghai Weizhou Biotechnology Co., Ltd.
・企業情報
・多価肺炎球菌複合体ワクチン製品
・多価肺炎球菌複合体ワクチン販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Multivalent Pneumococcal Conjugate Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Multivalent Pneumococcal Conjugate Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Multivalent Pneumococcal Conjugate Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Multivalent Pneumococcal Conjugate Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Multivalent Pneumococcal Conjugate Vaccine players cover Merck Sharp & Dohme Corp, Pfizer, CanSino Bio, Serum Institute of India Pvt. Ltd. and Shanghai Weizhou Biotechnology Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)’ newest research report, the “Multivalent Pneumococcal Conjugate Vaccine Industry Forecast” looks at past sales and reviews total world Multivalent Pneumococcal Conjugate Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Multivalent Pneumococcal Conjugate Vaccine sales for 2023 through 2029. With Multivalent Pneumococcal Conjugate Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multivalent Pneumococcal Conjugate Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Multivalent Pneumococcal Conjugate Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multivalent Pneumococcal Conjugate Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Multivalent Pneumococcal Conjugate Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multivalent Pneumococcal Conjugate Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multivalent Pneumococcal Conjugate Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Multivalent Pneumococcal Conjugate Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
13 Price
20 Price
23 Price
24 Price
Segmentation by application
Hospital
Outpatient Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Merck Sharp & Dohme Corp
Pfizer
CanSino Bio
Serum Institute of India Pvt. Ltd.
Shanghai Weizhou Biotechnology Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Multivalent Pneumococcal Conjugate Vaccine market?
What factors are driving Multivalent Pneumococcal Conjugate Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multivalent Pneumococcal Conjugate Vaccine market opportunities vary by end market size?
How does Multivalent Pneumococcal Conjugate Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Multivalent Pneumococcal Conjugate Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Multivalent Pneumococcal Conjugate Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Multivalent Pneumococcal Conjugate Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Multivalent Pneumococcal Conjugate Vaccine Segment by Type
2.2.1 13 Price
2.2.2 20 Price
2.2.3 23 Price
2.2.4 24 Price
2.3 Multivalent Pneumococcal Conjugate Vaccine Sales by Type
2.3.1 Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Multivalent Pneumococcal Conjugate Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Multivalent Pneumococcal Conjugate Vaccine Sale Price by Type (2018-2023)
2.4 Multivalent Pneumococcal Conjugate Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Outpatient Center
2.4.3 Others
2.5 Multivalent Pneumococcal Conjugate Vaccine Sales by Application
2.5.1 Global Multivalent Pneumococcal Conjugate Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Multivalent Pneumococcal Conjugate Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Multivalent Pneumococcal Conjugate Vaccine Sale Price by Application (2018-2023)
3 Global Multivalent Pneumococcal Conjugate Vaccine by Company
3.1 Global Multivalent Pneumococcal Conjugate Vaccine Breakdown Data by Company
3.1.1 Global Multivalent Pneumococcal Conjugate Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Multivalent Pneumococcal Conjugate Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Company (2018-2023)
3.2.2 Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Multivalent Pneumococcal Conjugate Vaccine Sale Price by Company
3.4 Key Manufacturers Multivalent Pneumococcal Conjugate Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multivalent Pneumococcal Conjugate Vaccine Product Location Distribution
3.4.2 Players Multivalent Pneumococcal Conjugate Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Multivalent Pneumococcal Conjugate Vaccine by Geographic Region
4.1 World Historic Multivalent Pneumococcal Conjugate Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Multivalent Pneumococcal Conjugate Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Multivalent Pneumococcal Conjugate Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Multivalent Pneumococcal Conjugate Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Multivalent Pneumococcal Conjugate Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Multivalent Pneumococcal Conjugate Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Multivalent Pneumococcal Conjugate Vaccine Sales Growth
4.4 APAC Multivalent Pneumococcal Conjugate Vaccine Sales Growth
4.5 Europe Multivalent Pneumococcal Conjugate Vaccine Sales Growth
4.6 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Growth
5 Americas
5.1 Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Country
5.1.1 Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Country (2018-2023)
5.1.2 Americas Multivalent Pneumococcal Conjugate Vaccine Revenue by Country (2018-2023)
5.2 Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Type
5.3 Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Region
6.1.1 APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Region (2018-2023)
6.1.2 APAC Multivalent Pneumococcal Conjugate Vaccine Revenue by Region (2018-2023)
6.2 APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Type
6.3 APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Multivalent Pneumococcal Conjugate Vaccine by Country
7.1.1 Europe Multivalent Pneumococcal Conjugate Vaccine Sales by Country (2018-2023)
7.1.2 Europe Multivalent Pneumococcal Conjugate Vaccine Revenue by Country (2018-2023)
7.2 Europe Multivalent Pneumococcal Conjugate Vaccine Sales by Type
7.3 Europe Multivalent Pneumococcal Conjugate Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine by Country
8.1.1 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales by Type
8.3 Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multivalent Pneumococcal Conjugate Vaccine
10.3 Manufacturing Process Analysis of Multivalent Pneumococcal Conjugate Vaccine
10.4 Industry Chain Structure of Multivalent Pneumococcal Conjugate Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multivalent Pneumococcal Conjugate Vaccine Distributors
11.3 Multivalent Pneumococcal Conjugate Vaccine Customer
12 World Forecast Review for Multivalent Pneumococcal Conjugate Vaccine by Geographic Region
12.1 Global Multivalent Pneumococcal Conjugate Vaccine Market Size Forecast by Region
12.1.1 Global Multivalent Pneumococcal Conjugate Vaccine Forecast by Region (2024-2029)
12.1.2 Global Multivalent Pneumococcal Conjugate Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Multivalent Pneumococcal Conjugate Vaccine Forecast by Type
12.7 Global Multivalent Pneumococcal Conjugate Vaccine Forecast by Application
13 Key Players Analysis
13.1 Merck Sharp & Dohme Corp
13.1.1 Merck Sharp & Dohme Corp Company Information
13.1.2 Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
13.1.3 Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Sharp & Dohme Corp Main Business Overview
13.1.5 Merck Sharp & Dohme Corp Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
13.2.3 Pfizer Multivalent Pneumococcal Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 CanSino Bio
13.3.1 CanSino Bio Company Information
13.3.2 CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
13.3.3 CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 CanSino Bio Main Business Overview
13.3.5 CanSino Bio Latest Developments
13.4 Serum Institute of India Pvt. Ltd.
13.4.1 Serum Institute of India Pvt. Ltd. Company Information
13.4.2 Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Serum Institute of India Pvt. Ltd. Main Business Overview
13.4.5 Serum Institute of India Pvt. Ltd. Latest Developments
13.5 Shanghai Weizhou Biotechnology Co., Ltd.
13.5.1 Shanghai Weizhou Biotechnology Co., Ltd. Company Information
13.5.2 Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
13.5.3 Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Shanghai Weizhou Biotechnology Co., Ltd. Main Business Overview
13.5.5 Shanghai Weizhou Biotechnology Co., Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Multivalent Pneumococcal Conjugate Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Multivalent Pneumococcal Conjugate Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 13 Price
Table 4. Major Players of 20 Price
Table 5. Major Players of 23 Price
Table 6. Major Players of 24 Price
Table 7. Global Multivalent Pneumococcal Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 8. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type (2018-2023)
Table 9. Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Type (2018-2023) & ($ million)
Table 10. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Type (2018-2023)
Table 11. Global Multivalent Pneumococcal Conjugate Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Multivalent Pneumococcal Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 13. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Application (2018-2023)
Table 14. Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Application (2018-2023)
Table 15. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Application (2018-2023)
Table 16. Global Multivalent Pneumococcal Conjugate Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Multivalent Pneumococcal Conjugate Vaccine Sales by Company (2018-2023) & (K Units)
Table 18. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Company (2018-2023)
Table 19. Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Company (2018-2023)
Table 21. Global Multivalent Pneumococcal Conjugate Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Multivalent Pneumococcal Conjugate Vaccine Producing Area Distribution and Sales Area
Table 23. Players Multivalent Pneumococcal Conjugate Vaccine Products Offered
Table 24. Multivalent Pneumococcal Conjugate Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Multivalent Pneumococcal Conjugate Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share Geographic Region (2018-2023)
Table 29. Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Multivalent Pneumococcal Conjugate Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country/Region (2018-2023)
Table 33. Global Multivalent Pneumococcal Conjugate Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 36. Americas Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 37. Americas Multivalent Pneumococcal Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 39. Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 40. Americas Multivalent Pneumococcal Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 41. APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Region (2018-2023) & (K Units)
Table 42. APAC Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Region (2018-2023)
Table 43. APAC Multivalent Pneumococcal Conjugate Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Region (2018-2023)
Table 45. APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 46. APAC Multivalent Pneumococcal Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 47. Europe Multivalent Pneumococcal Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 48. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 49. Europe Multivalent Pneumococcal Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 51. Europe Multivalent Pneumococcal Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 52. Europe Multivalent Pneumococcal Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Multivalent Pneumococcal Conjugate Vaccine
Table 60. Key Market Challenges & Risks of Multivalent Pneumococcal Conjugate Vaccine
Table 61. Key Industry Trends of Multivalent Pneumococcal Conjugate Vaccine
Table 62. Multivalent Pneumococcal Conjugate Vaccine Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Multivalent Pneumococcal Conjugate Vaccine Distributors List
Table 65. Multivalent Pneumococcal Conjugate Vaccine Customer List
Table 66. Global Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Multivalent Pneumococcal Conjugate Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Merck Sharp & Dohme Corp Basic Information, Multivalent Pneumococcal Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
Table 82. Merck Sharp & Dohme Corp Multivalent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Merck Sharp & Dohme Corp Main Business
Table 84. Merck Sharp & Dohme Corp Latest Developments
Table 85. Pfizer Basic Information, Multivalent Pneumococcal Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 86. Pfizer Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
Table 87. Pfizer Multivalent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Pfizer Main Business
Table 89. Pfizer Latest Developments
Table 90. CanSino Bio Basic Information, Multivalent Pneumococcal Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
Table 92. CanSino Bio Multivalent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. CanSino Bio Main Business
Table 94. CanSino Bio Latest Developments
Table 95. Serum Institute of India Pvt. Ltd. Basic Information, Multivalent Pneumococcal Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
Table 97. Serum Institute of India Pvt. Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Serum Institute of India Pvt. Ltd. Main Business
Table 99. Serum Institute of India Pvt. Ltd. Latest Developments
Table 100. Shanghai Weizhou Biotechnology Co., Ltd. Basic Information, Multivalent Pneumococcal Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Product Portfolios and Specifications
Table 102. Shanghai Weizhou Biotechnology Co., Ltd. Multivalent Pneumococcal Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Shanghai Weizhou Biotechnology Co., Ltd. Main Business
Table 104. Shanghai Weizhou Biotechnology Co., Ltd. Latest Developments
List of Figures
Figure 1. Picture of Multivalent Pneumococcal Conjugate Vaccine
Figure 2. Multivalent Pneumococcal Conjugate Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multivalent Pneumococcal Conjugate Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Multivalent Pneumococcal Conjugate Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 13 Price
Figure 10. Product Picture of 20 Price
Figure 11. Product Picture of 23 Price
Figure 12. Product Picture of 24 Price
Figure 13. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type in 2022
Figure 14. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Type (2018-2023)
Figure 15. Multivalent Pneumococcal Conjugate Vaccine Consumed in Hospital
Figure 16. Global Multivalent Pneumococcal Conjugate Vaccine Market: Hospital (2018-2023) & (K Units)
Figure 17. Multivalent Pneumococcal Conjugate Vaccine Consumed in Outpatient Center
Figure 18. Global Multivalent Pneumococcal Conjugate Vaccine Market: Outpatient Center (2018-2023) & (K Units)
Figure 19. Multivalent Pneumococcal Conjugate Vaccine Consumed in Others
Figure 20. Global Multivalent Pneumococcal Conjugate Vaccine Market: Others (2018-2023) & (K Units)
Figure 21. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Application (2022)
Figure 22. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Application in 2022
Figure 23. Multivalent Pneumococcal Conjugate Vaccine Sales Market by Company in 2022 (K Units)
Figure 24. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Company in 2022
Figure 25. Multivalent Pneumococcal Conjugate Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Company in 2022
Figure 27. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Multivalent Pneumococcal Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 30. Americas Multivalent Pneumococcal Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. APAC Multivalent Pneumococcal Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 32. APAC Multivalent Pneumococcal Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Europe Multivalent Pneumococcal Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 34. Europe Multivalent Pneumococcal Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 37. Americas Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country in 2022
Figure 38. Americas Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 39. Americas Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 40. Americas Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 41. United States Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Region in 2022
Figure 46. APAC Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Regions in 2022
Figure 47. APAC Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 48. APAC Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 49. China Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country in 2022
Figure 57. Europe Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 58. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 59. Europe Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 60. Germany Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Multivalent Pneumococcal Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 69. Egypt Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Multivalent Pneumococcal Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Multivalent Pneumococcal Conjugate Vaccine in 2022
Figure 75. Manufacturing Process Analysis of Multivalent Pneumococcal Conjugate Vaccine
Figure 76. Industry Chain Structure of Multivalent Pneumococcal Conjugate Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Forecast by Region (2024-2029)
Figure 79. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Multivalent Pneumococcal Conjugate Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Multivalent Pneumococcal Conjugate Vaccine Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の多価肺炎球菌複合体ワクチン市場予測 2023年-2029年] (コード：LP23DC05671)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の多価肺炎球菌複合体ワクチン市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の結合型ワクチン市場2022-2029：種類別（一価結合型ワクチン、多価結合型ワクチン）、疾患別（肺炎球菌、インフルエンザ、ジフテリア・破傷風・百日咳（DTP）、髄膜炎菌感染症、その他）、病原体種類別（細菌結合型ワクチン、ウィルス結合型ワクチン、混合（ウイルス・細菌）結合型ワクチン）、エンドユーザー別（小児科、成人）、地域別
  • 世界の10価肺炎球菌結合型ワクチン市場予測2023-2029：単回投与バイアル、プレフィルドシリンジ
  • 世界の経口腸チフスワクチン市場予測 2023年-2029年
  • 世界の犬用ボルデテラワクチン市場予測 2023年-2029年
  • 世界の経口ボルデテラワクチン市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆